據報康希諾生物(06185.HK)正向歐洲國家洽售新冠疫苗
據《彭博通訊社》報道,康希諾生物(06185.HK)表示,正與歐洲一些國家洽售其新冠疫苗。倘歐洲採購康希諾的疫苗,將標志著中國製造新冠疫苗在全球推廣的重大突破。
報告引述公司負責國際業務的高級副總裁Pierre Morgon稱,三個歐盟成員國已接洽公司討論潛在購買事宜。
康希諾生物周一(22日)表示,其新冠疫苗已經獲得匈牙利國家藥品與營業研究所(OGYEI)的緊急使用授權;這為該公司單針疫苗在當地使用鋪平了道路。Morgon表示,正在考慮擴大監管足跡,而歐洲肯定在內。匈牙利正在給整個局勢帶來轉折,因為它是一個歐洲國家
報告稱,雖然在目前全球可用的12種疫苗中,有四種來自中國這世界第二大經濟體;但其疫苗主要流向那些難以獲取西方公司,如輝瑞(PFE.US)和阿斯利康(AZN.US)之疫苗的開發中國家。西方公司的疫苗絕大部分流向了美國和其他富裕國家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.